Logo

STOK

Stoke Therapeutics, Inc.

STOK

Stoke Therapeutics, Inc. • NASDAQ
$30.91 ▼ -0.96% (-0.30)
Market Cap $1.77 B
52w High $38.69
52w Low $5.35
Dividend Yield 0%
P/E 45.46
Volume 318.77K
Outstanding Shares 57.12M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $10.632M ▼ $52.734M ▲ $-38.347M ▼ -360.675% ▼ $-0.65 ▼ $-38.633M ▼
Q2-2025 $13.817M ▼ $41.117M ▼ $-23.483M ▼ -169.957% ▼ $-0.4 ▼ $-26.854M ▼
Q1-2025 $158.569M ▲ $47.329M ▲ $112.879M ▲ 71.186% ▲ $1.95 ▲ $111.717M ▲
Q4-2024 $22.614M ▲ $36.267M ▲ $-10.482M ▲ -46.352% ▲ $-0.18 ▲ $-13.127M ▲
Q3-2024 $4.894M $34.897M $-26.43M -540.049% $-0.47 $-29.463M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $248.31M ▲ $360.264M ▼ $52.159M ▲ $308.105M ▼
Q2-2025 $247.708M ▼ $384.508M ▼ $49.565M ▼ $334.943M ▼
Q1-2025 $357.324M ▲ $406.888M ▲ $56.814M ▲ $350.074M ▲
Q4-2024 $216.899M ▼ $271.555M ▼ $42.534M ▼ $229.021M ▼
Q3-2024 $239.2M $293.319M $61.206M $232.113M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-38.347M ▼ $-30.366M ▼ $9.094M ▲ $3.12M ▲ $-18.153M ▲ $-30.498M ▼
Q2-2025 $-23.482M ▼ $-25.422M ▼ $-148.477M ▼ $554K ▼ $-173.345M ▼ $-25.576M ▼
Q1-2025 $112.879M ▲ $131.827M ▲ $13.632M ▲ $1.374M ▲ $146.833M ▲ $131.675M ▲
Q4-2024 $-10.482M ▲ $-23.193M ▼ $819K ▲ $568K ▼ $-21.806M ▲ $-23.235M ▼
Q3-2024 $-26.43M $-21.615M $-30.004M $8.159M $-43.46M $-21.718M

Five-Year Company Overview

Income Statement

Income Statement Stoke looks like a classic clinical‑stage biotech: almost no product revenue yet and steady, meaningful losses every year. The company’s operating and net losses have been fairly consistent over the last few years, reflecting ongoing spending on research, clinical trials, and overhead without any approved drugs to offset those costs. Per‑share losses have been sizable, though they have recently improved a bit from their worst levels. Overall, the income statement shows a business still firmly in the investment phase, dependent on external funding and partnerships rather than internal profits.

Balance Sheet

Balance Sheet The balance sheet is relatively clean and simple. Stoke holds a sizable portion of its assets in cash and has no financial debt, which reduces interest and refinancing risk. However, cash levels have trended down from earlier years as the company funds operations, and shareholders’ equity has also eroded over time as losses accumulate. The company still has a positive capital base, but the pattern suggests that, absent new capital or major milestone payments, future dilution or other financing steps are likely over time to support its programs.

Cash Flow

Cash Flow Cash flow behavior reinforces the early‑stage profile. The business consistently uses cash in its day‑to‑day operations, with outflows tied mainly to R&D and overhead. Free cash flow is negative but has been relatively stable, and capital spending is minimal, so cash burn is mostly about running trials and advancing the pipeline rather than building physical assets. This is typical for a platform biotech, but it also means future progress depends heavily on maintaining access to capital markets and partners as current cash is drawn down.

Competitive Edge

Competitive Edge Stoke’s competitive strength comes from its specialized TANGO platform, which is designed to boost output from a healthy copy of a gene in diseases caused by partial loss of function. This gives it a differentiated angle versus traditional gene therapy, with advantages like being mutation‑agnostic and reversible. Strong intellectual property, a focused niche in haploinsufficiency disorders, and partnerships with well‑known pharma companies strengthen its position. On the other hand, the company operates in a crowded, fast‑moving genetic medicines space, competing with gene therapies and other RNA approaches from well‑funded rivals, and it still needs late‑stage clinical proof to cement its place.

Innovation and R&D

Innovation and R&D Innovation is clearly Stoke’s core asset. The TANGO antisense platform targets RNA splicing to restore protein levels, which, if successful, could be broadly applied to many genetic diseases. The lead program, zorevunersen for Dravet syndrome, aims to be a first disease‑modifying therapy, while STK‑002 extends the approach into inherited vision loss. The company devotes substantial resources to R&D and has expanded its reach through collaborations on other neurodevelopmental conditions. The upside is a potentially versatile technology with multiple shots on goal; the downside is heavy dependence on clinical trial outcomes and regulatory acceptance of a relatively novel mechanism.

Summary

Overall, Stoke is a high‑risk, high‑uncertainty, early‑stage biotech built around a promising platform rather than an existing commercial business. Financials show ongoing losses, cash burn, and no real revenue, but also a debt‑free balance sheet and a clear allocation of resources toward R&D. The scientific story and partnerships provide meaningful upside potential if pivotal trials succeed and regulatory paths are smooth. At the same time, there are significant risks around trial results, timelines, funding needs, and competition from other genetic medicine approaches. This is a story driven more by future clinical and regulatory milestones than by current financial performance.

NEWS

November 18, 2025 · 4:01 PM UTC

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Read more

November 17, 2025 · 7:30 AM UTC

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Read more

November 4, 2025 · 4:01 PM UTC

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Read more

October 30, 2025 · 4:30 PM UTC

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

Read more

October 20, 2025 · 7:30 AM UTC

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

Read more